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Mitochondria regulate energy metabolism, biosynthesis, cell death, redox homeostasis and 
signaling pathway and dysregulated mitochondria abundantly observed in cancer. Therefore, 
researchers tried to targeting mitochondria for killing cancer. The mitochondrial fission factor (MFF) 
and voltage-dependent anion channel (VDAC) form a complex which of interruption activates 
mitochondrial outer membrane permeability (MOMP) and induces cell death. MFF peptide, synthetic 
MFF sequence peptide that competitively inhibit MFF and VDAC interaction, treatment leads to 
mitochondrial cell death in cancer but not in normal. However, due to poor stability of peptide in vivo, 
it is needed to develop new substance that inducing cell death via interfering of MFF-VDAC interaction 
like MFF peptide. We developed chemical screening system to seek chemical interfering MFF-VDAC 
interaction using nanobit protein-protein interaction assay system which is structural complementation 
reporter system. The chemical identified from this assay system could be a new anti-cancer drug that is 
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1.1 Mitochondria and cancer 
In the past, there is a misunderstanding that mitochondria activity would not be important in 
cancer because of ‘Warburg effect’ that cancer use glycolysis for energy production despite presence of 
oxygen for mitochondrial respiration. However, continuous studies revealed that mitochondrial 
respiration still possess high proportion of energy production in cancer which display Warburg 
metabolism and even some cancer have high dependence of mitochondrial respiration.  
 Typically, Tumor cells form tumor mass through uncontrollable and undiscriminating cell 
proliferation. As tumor mass become bigger and bigger, they encounter various cellular stress such as 
hypoxia, inflammation, nutrient deprivation, and oxidative stress. Also, cancer meets these stresses 
during progression. Thus, for cancer to develop and progress to next stage, they must overcome harsh 
environment arose from cellular stresses. In this situation, mitochondria contribute to enduring cellular 
stresses and support cancer to initiate and progress (Figure 1.1). For example, cancer produce energy 
from mitochondria when cancer are in nutrient-deprived condition. 
 The major role of mitochondria is producing energy through oxidation phosphorylation 
(OXPHOS) pathway connected with tricarboxylic acid cycle (TCA cycle) and Fatty acid oxidation 
(FAO).1 Cancer prefer to use glycolysis for energy production to support rapid proliferation, therefore, 
cancer consume lots of glucose.2 However, even though cancer conjugate glycolysis, it’s not means 
cancer do not use mitochondria because of efficiency of energy production and flexible alteration of 
mitochondrial metabolism. Furthermore, when tumor mass encounter nutrient-deprived condition by 
excessive growth, tumor cells can use other carbon sources such as lactate, acetate, glycine, and serine 
for mitochondrial energy production (Figure 1.2).3,4,5 And recent researches show that some cancer type 
or metastatic cancer have high dependence of mitochondrial energy production.6,7 It means that 
mitochondria is essential organelle to cancer cell to survive in harsh environment and progress to next 
stage. 
 
1.2 Mitochondrial Outer Membrane Permeabilization (MOMP) : the door of programmed cell 
death 
 In general, normal cells undergo programmed cell death when cells get severe damage from 
cellular stresses. The death signaling are activated in response to cellular stresses and initiate apoptosis 
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through mitochondrial outer membrane permeabilization (MOMP). Once MOMP is triggered in cells, 
there is nothing to return apoptosis back. Thus, MOMP is known as the point of no return for apoptosis. 
At this point, mitochondria play central role as mediator of MOMP. MOMP occurred by activating pro-
apoptotic Bcl2 family proteins : Bax and Bak. The death signaling activates Bax to make pore in 
mitochondrial outer membrane via homo-oligomerization or hetero-oligomerization with Bak and 
VDAC (Figure 1.4). This pore releases mitochondrial intraspace proteins such as SMAC and 
cytochrome c. Then, they activate caspases that is executer of cell degradation (Figure 1.3). 
 
1.3 A Cancer Hallmark : Avoiding cell death 
 Cancer could avoid the cell death, which is one of cancer hallmarks, blocking MOMP through 
various ways. As mentioned above, normal cells activate MOMP in response to intrinsic lethal stimuli. 
However, in cancer cell, despite of intrinsic lethal stimuli, Bax and Bak failed to forming pores in 
several ways. Then, cancer avoid cell death. A way of avoiding cell death is upregulating anti-apoptotic 
proteins and inhibitor of apoptosis proteins. They inhibit the activation of Bax and Bak blocking pore 
construction. Also, downregulation and silence mutation of pro-apoptotic proteins prevent Bax and Bak 
to make pores (Figure 1.5). Thus, failure to forming pores prevent MOMP then, finally cancer cell could 
avoid cell death in presence of intrinsic lethal stimuli. Furthermore, cancer cells appear drug resistance 
by preventing MOMP.  
 
1.4 Targeting mitochondria for treatment of cancer 
 Recent researches revealed that mitochondria is dysregulated by overexpression of oncogenes 
and loss function of tumor suppressor genes in cancer. Dysregulated mitochondria support initiation of 
tumorigenesis and tumor cell survival encountered harsh environment such as hypoxia, nutrient-
deprived condition, and metabolic stress.32 Some cancers are highly dependent on mitochondrial 
metabolism and inhibition of mitochondrial activity promotes repression of cell proliferation and cell 
death.33 As conquering dysregulated mitochondria mechanism and vulnerabilities, targeting 











Figure 1.1 Mitochondria support cancer at multiple stages 















Figure 1.2 Cancer cell mitochondrial metabolism in nutrient-deprived conditions 














Figure 1.3 Mitochondrial outer membrane permeabilization induces cell death 















Figure 1.4 Bax makes pore in mitochondrial outer membrane via homo-oligomerization or 
hetero-oligomerization with Bak and VDAC 



















Figure 1.5 Cancer avoid cell death through several ways in presence of intrinsic lethal stimuli 
(2019). Contribution of Mitochondrial Ion Channels to Chemo-Resistance in Cancer 
Cells. Cancers, 11(6), 761 














Mitochondria regulate several kinds of programmed cell death (PCD) such as apoptosis and 
necroptosis.39,40 And PCD is essential natural mechanism and one of defense mechanism in response to 
severe DNA damage, pathogen infection and uncontrolled cell proliferation. Thereby, tissues and cells 
maintain cell homeostasis and healthy condition preventing excessive cell proliferation and a series of 
infection. Since PCD is determines survival or death of cells, it tightly regulated by cell signaling 
pathway that mitochondria is centered. Among PCD process, mitochondrial outer membrane 
permeabilization (MOMP) is most important step known as the point of no return because nothing can 
take apoptotic signaling back once stimulated.41 However, cancer have ability to avoid apoptosis 
through dysregulated mitochondria. Therefore, researchers tried to targeting mitochondria for cancer 
therapy inducing PCD. 
 Our laboratory previously studied trying to find effective anti-cancer drug targeting 
mitochondria. The central topic was mitochondrial fission factor (MFF) known as regulator of 
mitochondrial fission with Drp1 and overexpressed in prostate cancer. The proteomics result for MFF-
associated proteins shows MFF interacts with VDAC that forms MOMP regulating complex.42 Indeed, 
regulation of MFF by siRNA shows reduction of mitochondrial potential. This result suggests the 
unknown function of MFF in cancer. 
 The Nanobit PPI (protein-protein interaction) assay used to develop cancer cell death inducer 
screening system to search chemical act like MFF peptide. Nanobit PPI assay is structural 
complementation reporter system composed of two subunits; one is Large bit (18kDa) and the other is 
small complimentary peptide (11 amino acid peptide). Each subunit can tag to interest of protein and 
express in cell line. When the two proteins interact in cell, the nanobit subunits also interact together 
generating luminescent signal in the presence of substrate.43 Furthermore, two subunits interaction is 
reversible, enabling detection of luminescent signal in real time and even detectable in live cell. 
 Here, we found MFF and VDAC interact with each other and interfering with interaction 
induces cancer cell death. In turn, we developed chemical screening system to find chemical like MFF 
peptide which is suggested to anti-cancer drug that is new targeting in mitochondria. 
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 The following antibodies to Mitochondrial fission factor (MFF, Protein Tech, 17090-1-AP), 
Voltage-dependent anion channel (VDAC, Abcam, ab15895), β-actin (GeneTex, GTX629630), Flag 
(Cell signaling, 14793) were used. 
 
Cell culture 
 DU145 and PC3 cells cultured in Roswell Park Memorial Institute (RPMI 1640), with L-
Glutamine and 25mM HEPES, 1L (Lonza, 12-702f) containing 10% Fetal Bovine Serum (Gibco, 
16000044) and 1% antibiotics (100ml antibiotic-antimycotic, 100x, Gibco, 15240062) at 37 °C under 
a humidified 5% CO2 atmosphere. Ct26, B16F10 and HEK293 cells cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) and other conditions identical with above. All cells were purchased from 
the American Type Culture (ATCC). 
 
Cell growth and Cell death measurement 
 MFF peptide treated cells were detached using trypsin-EDTA (0.25%, Gibco, 25200056) and 
suspended cell were blended with Trypan blue stain (0.4%, Gibco, 15250-061) with equal volume. 
10μl of blended cells were filled in CountessTM cell counting chamber slides (Thermo Fischer 
Scientific, C10228) and counted by CountessTM FL automated cell counter. Counted variable cell 
number divided into control cell number and calculated in percentage. 
 
Transfection 
 For gene knockdown transfection, siRNA mixed with RNAimax (Thermo Fischer Sciencific, 
13778030) in the Opti-MEM (Gibco, 31985070) and incubates for 20 min. Mixture added to culturing 
media. For overexpression transfection, plasmid and jetPEI (polyplus, 101-10N) mixed by mass ratio 
1:2 with NaCl solution. After incubating for 15 min, mixture added to cultured media without 
antibiotics. After 4h, media change to fresh. 
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Western blot analysis 
 Protein lysate were prepared in radioimmunoprecipitation (RIPA) buffer (25 mM Tris-HCl/pH 
7.6, 150 mM NaCl, 1% NP-40, 1% Sodium deoxycholate, 1% SDS, Biomax) containing a cocktail of 
proteinase inhibitors and phosphatase inhibitors (100x, Thermo Fischer Scientific, 1861281). And cells 
are harvested. The concentration of total proteins was measured with BCA reagent (Thermo Fischer 
Scientific, 23235). Loaded proteins were separated with 8~13% SDS-PAGE and transferred to PVDF 
membranes (Millipore Sigma, 88518). 5% (w/v) skim-milk was used for blocking and primary 
antibodies, which has refereed, were incubated overnight at 4°C. After washing with Tris-buffered 
saline containing Tween 20 (TBS-T) for 3 times every each 10 min, the membranes were incubated 
with horseradish peroxidase (HRP)-labeled secondary antibodies for 1 hour and visualized by ECL 
and ECL prime reagents (GE Healthcare, RPN2232). 
 
Immunoprecipitation 
 IP buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA) containing 1% CHAPS, 
EDTA-free Protease Inhibitor Cocktail (Sigma-Aldrich) and Phosphatase Inhibitor Cocktail 
PhosSTOP (Roche) were prepared. And cells were harvested and lysed. Then, lysates were sonicated 
and centrifuged at 15,000 x g for 30 min. And cell lysates were incubated with anti-Flag-conjugated 
beads (Sigma-Aldrich). The precipitates were washed five times with PBS, separated by sodium 




 The pBiT vectors (pBiT1.1-N[TK/LgBiT], pBiT1.1-C[TK/LgBiT], pBiT2.1-N[TK/SmBiT], 
pBiT2.1-C[TK/SmBiT]) were purchased from Promega (NanoBiT® PPI MCS starter System Vectors, 
N2014). MFF and VDAC genes cloned into each pBiT vectors using BiT-MFF primers (5’-
CCGCTCGAGCGGTATGGCAGAAATTAGTCGAATTCAG-3’ and 5’-CTAGCTAGCCTAGCGGC 
GAAACCAGAGCCA-3’), MFF-BiT primers (5’-CTAGCTAGCATGGCAGAAATTAGTCGAATTC 
AG-3’ and 5’-CCGCTCGAGCCGCGGCGAAACCAGAGCCAGCT-3’), BiT-VDAC primers (5’-
CCGCTCGAGCGGTATGGCTGTGCCACCCACGTATGC-3’ and  5’-CTAGCTAGCTTATGCTT 
GAAATTCCAGTCCTAG-3’), VDAC-BiT primers (5’-CTAGCTAGCATGGCTGTGCCACCCACG 
TATGC-3’ and 5’-CGGCTCGAGCCTGCTTGAAATTCCAGTCCTAGACC-3’). Then, for high 
plasmid expression level in cells, nanobit tagged genes were cloned into pcDNA3.1(+) vectors. 
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Nanobit PPI assay 
 Cells plated on white 96 well plate for measurement of luminescent signal. Preparing the 
desired amount of reconstituted Nano-Glo® Live Cell Reagent by combining 1 volume of Nano-Glo® 
Live Cell Substrate with 19 volumes of Nano-Glo® LCS Dilution Buffer (a 20-foled dilution), creating 
a 5X stock to mix with cell culture medium. Then measuring baseline luminescence and right after 
treat peptides and with time intervals. 
 
TMRE assay 
 Cells are plated on black 96 well cell plate. The final concentration 100 nM TMRE 
(Thermofisher, T669) added to cultured medium with cell for staining. After 20 min, washing 3 times 




















MFF and VDAC interact with each other and MFF peptide treatment interferes with MFF-VDAC 
interaction 
In previous study of our laboratory, the proteomic result suggests MFF and VDAC may 
interact with each other forming MOMP regulating complex at mitochondrial outer membrane. First, 
we confirmed MFF and VDAC interaction by co-immunoprecipitation. We expressed flag tagged MFF 
or VDAC, respectively with normal partner protein, and pulled down by flag antibody. As a result, flag-
MFF interacted with VDAC and flag-VDAC interacted with MFF demonstrating MFF and VDAC 
interact with each other (Figure 2.1A and 2.1B). Furthermore, when flag-VDAC and GFP-MFF co-
expressed and pulled down by flag antibody, MFF was detected by GFP antibody (Figure 2.1C). It 
provides high reliability clue that MFF-VDAC interact with each other. In previous study, we found a 
part of MFF sequence, the MFF peptide that reduced mitochondrial membrane potential similar with 
siMFF treatment. Then, we investigated whether MFF peptide treatment affect to MFF-VDAC 
interaction. We treated scr peptide and MFF peptide in flag-VDAC expressed cells and observed MFF 
expression in co-immunoprecipitation with flag antibody. Then, we observed that pulled down MFF 
with flag antibody was decreased in MFF peptide treatment contrast to scr peptide treatment (Figure 
2.1D). Therefore, MFF peptide treatment interferes with MFF-VDAC interaction. 
 
MFF peptide treatment induces cell death through activating MOMP 
 Then, to investigate whether MFF-VDAC interaction affects to cell viability, we observed cell 
growth and cell death with MFF peptide dese-dependent treatment. Cell growth were measured by 
percentage of lived cell number contrast to before treated, and cell death were measured by percentage 
of dead cell number contrast to total cell number. The rate of cell growth decreased by treatment of 
MFF peptide dose-dependently (Figure 2.2A). And cell death increased with same experimental 
condition of cell growth (Figure 2.2B). Because programmed cell death is known to be initiated by 
MOMP, we measured mitochondrial membrane potential by staining TMRE (Figure 2.2C - 2.2E). MFF 
peptide treatment decreased mitochondrial membrane potential coupled with MOMP suggesting MFF 




LgBiT-MFF and SmBiT-VDAC are proper combination to express highest luminescent activity 
Since MFF peptide has several disadvantages such as high production cost, in vivo instability 
and low membrane permeability, it depreciates the value as anti-cancer drug. Therefore, we need to 
search substance that interfering MFF-VDAC complex like MFF peptide and simultaneously covers 
disadvantages of MFF peptide. To search wanted substance, we developed chemical screening system 
using Nanobit PPI assay which system is detecting chemicals that interfering MFF-VDAC interaction 
like MFF peptide in live cell (Figure 2.5A). To construct a chemical screening system with Nanobit PPI 
assay, the two subunits must interact with each other properly. However, since we do not know structure 
of MFF and VDAC, and how they interact with, we have to consider the possibilities of all combinations 
of subunits. Thus, we produced nanobit subunit tagged protein plasmid and tuned the expression level 
of nanobit tagged proteins as similar as possible (Figure 2.5B) because we have to find best combination 
which generate highest luminescent activity in same numbers of combination. Combinations that are 
composed with VDAC-LgBit did not shown in data because of poor expression level. 
 To discriminate which combination is the most suitable combination, the possibilities of all 
combinations were expressed in cells and the luminescent activity was measured. As a result, the 
combination of LgBiT-MFF and SmBiT-VDAC showed the highest activity over time than other 
combinations. Therefore, we confirmed that LgBiT-MFF and SmBiT-VDAC are the most optimal 
combination for chemical screening system (Figure 2.5C). 
 
MFF peptide efficiently decreases luminescent activity interfere with MFF-VDAC interaction 
Because we determined the most optimal combination for screening, we need to confirm 
whether luminescent activity is decreased by MFF peptide treatment. Therefore, we measured 
luminescent activity at LgBiT-MFF and SmBiT-VDAC co-expressed in cell with treatment of MFF 
peptide (Figure 2.6A). Before treatment of peptide, the luminescent activities of all samples are similar 
level (Figure 2.6B). However, luminescent activities are decreased by dose-dependently in MFF peptide 
treated cells after 120 minutes (Figure 2.6C). Furthermore, we confirmed MFF peptide function in essay 
used cell line. Decreased TMRE staining in MFF peptide treated cells suggest interfering of MFF-








Mitochondria have important role in cancer from initiation to metastasis. Various role of 
mitochondria such as metabolic reprogramming, redox homeostasis, evasion of cell death, biogenesis 
and mitochondrial dynamics supports cancer cells to survive in any circumstances.32 Therefore, 
targeting mitochondrial is one of strategy for cancer therapy. There are some therapeutic targets in 
mitochondria. Mutated IDH1/2 (isocitrate dehydrogenase; 1 in cytosol and 2 in mitochondria) produce 
D-2 hydroxyglutarate (D-2HG) known as a oncometabolite and mostly detected in acute myeloid 
leukemia (AML), bile duct cancer, bone sarcoma and glioma. They contribute to tumor initiation and 
progression through blocking cell differentiation and could be an anti-tumor target.34,35 As mentioned 
above, one carbon metabolism serves mitochondrial biomass synthesis. Since SHMT2 (serine 
hydroxymethyltransferase 2) is a crucial enzyme in synthesis of serine and glycine, inhibition of 
SHMT2 could block biomass synthesis and some research revealed that SHMT2 inhibition reduced 
cancer cell growth.36,37 Several anti-cancer drugs targeting mitochondrial OXPHOS pathway are widely 
used already.38 
 There are several assays for investigating PPI such as tandem affinity purification-mass 
spectroscopy (TAP-MS), affinity chromatography, co-immunoprecipitation and protein microarrays. 
Nanobit PPI assay has some advantages contrast to other PPI assay. First, nanobit subunits have small 
affinity with each other providing high accuracy of protein-protein interaction. And due to nanobit 
subunits interact reversibly, it allows detecting protein-protein interaction in real time and even 
detectable in live cell condition. 
 In case of our study, we figured out best combination of nanobit subunits in MFF and VDAC 
interaction. And we confirmed MFF peptide greatly decreases luminescent activity by interfering MFF-
VDAC interaction. As mentioned above, we need to identify MFF peptide like substance using chemical 
screening system we developed. There are some chemical libraries for testing our system. Next, we 
could figure out several chemicals that decreasing luminescent signaling in our system. That means 
chemicals effectively interfere with MFF-VDAC interaction. Then, we have to pick out optimal 
chemical through several experiments that proceeded with MFF peptide such as cell death rate and 
TMRE staining. The figured-out chemical could be a potential anti-cancer drug that effectively kill the 









Figure 2.1 MFF and VDAC interact with each other. 
(A-B) PC3 cells transfected with vector, Flag-MFF (A) or Flag-VDAC (B) were immunoprecipitated 
(IP) with an antibody to Flag and analyzed by western blotting. 
(C) PC3 cells transfected with vector, Flag-VDAC, GFP-MFF were immunoprecipitated with an 
antibody to Flag and analyzed by western blotting. 
(D) PC3 cells transfected with vector and Flag-VDAC and treated scr peptide or MFF peptide were 
































Figure 2.2 MFF peptide treatment decreases cell growth and increases cell death through MOMP 
(A) Cell growth were measured by percentage of lived cell number contrast to before treated MFF 
peptide. 
(B) Cell death was measured by percentage of dead cell number contrast to total cell number at each 
MFF peptide dose. 
(C) MFF peptide treatment in Ct26 and B16F10 cell lines analyzed for mitochondrial membrane 
potential analyzed by TMRE staining. FCCP was used as a control. 
(D-E) Fluorescence microscopy images of Ct26 and B16F10 treated MFF peptide and FCCP showing 






























































Figure 2.3 LgBiT-MFF and SmBiT-VDAC are proper combination to express highest luminescent 
activity 
(A) The scheme of chemical screening system using nanobit PPI assay. 
(B) All possibilities of nanobit combination transfected to HEK293 cell line 




















Figure 2.4 MFF peptide efficiently decreases luminescent activity interfere with MFF-VDAC 
interaction 
(A) Relative luminescent activity measured by time lapse in LgBiT-MFF and SmBiT-VDAC transfected 
HEK293 cell line 
(B) Luminescent activity measured when immediately nanobit substrate is added. 
























































Figure 2.5 MFF peptide treatment decreased mitochondrial activity in HEK293 cell line 
(A-B) Fluorescence microscopy images of Ct26 and B16F10 treated MFF peptide showing TMRE 
staining. Cell nucleus were stained with Hoechst 33342. 
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